U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H30O
Molecular Weight 310.473
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESOGESTREL

SMILES

CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

InChIKey=RPLCPCMSCLEKRS-BPIQYHPVSA-N
InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H30O
Molecular Weight 310.473
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Desogestrel is a prodrug of etonogestrel (3-keto-desogestrel) which was approved as oral contraceptove medicine. Desogestrel acts selectively binding to progesterone receptor and enchancing its activity.

Originator

Approval Year

1992
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8583
DESOGEN

Approved Use

Desogen (desogestrel and ethinyl estradiol) Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.69 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2147817/
0.15 mg 1 times / day steady-state, oral
dose: 0.15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2805 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
0.15 mg single, oral
dose: 0.15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 ETONOGESTREL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
5840 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
0.15 mg 1 times / day steady-state, oral
dose: 0.15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 ETONOGESTREL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2147817/
0.15 mg 1 times / day steady-state, oral
dose: 0.15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
33858 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
0.15 mg single, oral
dose: 0.15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 ETONOGESTREL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
52299 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
0.15 mg 1 times / day steady-state, oral
dose: 0.15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 ETONOGESTREL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2147817/
0.15 mg 1 times / day steady-state, oral
dose: 0.15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
0.15 mg single, oral
dose: 0.15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 ETONOGESTREL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
2%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
0.15 mg 1 times / day steady-state, oral
dose: 0.15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 ETONOGESTREL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 ug 1 times / day steady, oral
Recommended
Dose: 150 ug, 1 times / day
Route: oral
Route: steady
Dose: 150 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
healthy, mean 24.6 years
Health Status: healthy
Age Group: mean 24.6 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
Disc. AE: Headache, Depression...
AEs leading to
discontinuation/dose reduction:
Headache (> 0.45)
Depression (> 0.45)
Menorrhagia (> 0.45)
Skin disorder (> 0.45)
Emotional lability (> 0.45)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
AEs

AEs

AESignificanceDosePopulation
Depression > 0.45
Disc. AE
150 ug 1 times / day steady, oral
Recommended
Dose: 150 ug, 1 times / day
Route: oral
Route: steady
Dose: 150 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
healthy, mean 24.6 years
Health Status: healthy
Age Group: mean 24.6 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
Emotional lability > 0.45
Disc. AE
150 ug 1 times / day steady, oral
Recommended
Dose: 150 ug, 1 times / day
Route: oral
Route: steady
Dose: 150 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
healthy, mean 24.6 years
Health Status: healthy
Age Group: mean 24.6 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
Headache > 0.45
Disc. AE
150 ug 1 times / day steady, oral
Recommended
Dose: 150 ug, 1 times / day
Route: oral
Route: steady
Dose: 150 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
healthy, mean 24.6 years
Health Status: healthy
Age Group: mean 24.6 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
Menorrhagia > 0.45
Disc. AE
150 ug 1 times / day steady, oral
Recommended
Dose: 150 ug, 1 times / day
Route: oral
Route: steady
Dose: 150 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
healthy, mean 24.6 years
Health Status: healthy
Age Group: mean 24.6 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
Skin disorder > 0.45
Disc. AE
150 ug 1 times / day steady, oral
Recommended
Dose: 150 ug, 1 times / day
Route: oral
Route: steady
Dose: 150 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
healthy, mean 24.6 years
Health Status: healthy
Age Group: mean 24.6 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16542051/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
substrate
1193

OverviewOther

Other InhibitorOther SubstrateOther Inducer
MRP2
499

CYP2B6
926

P-gp
1741
CYP2C19
1119

CYP2E1
729
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
MRP2
625
 no
P-gp
1932
 yes
CYP2B6
1160
 yes
yes (co-administration study)
Comment: Subjects received a 10-day pretreatment with an oral contraceptive, containing 30 microg ethinyl estradiol (INN, ethinylestradiol) and 150 microg desogestrel, and the bupropion dose was given 1 hour after the last hormone dose. The bupropion, hydroxybupropion, and hydrobupropion plasma concentrations were determined for up to 72 hours.
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1193
 major
CYP2C19
1119
 minor
CYP2E1
729
 no
CYP3A4
1946
 no
CYP3A4
1946
 yes
3-ketodesogestrel
1
yes (co-administration study)
Comment: Pretreatment with itraconazole for 4 days significantly increased the area under the plasma concentration-time curve (AUC) of 3-keto-desogestrel by 72.4%
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4453
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4453
ChemicalBook
CB2359630
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2359630
eMolecules
2736265
https://www.emolecules.com/cgi-bin/more?vid=2736265
MolPort
MolPort-003-846-424
https://www.molport.com/shop/molecule-link/MolPort-003-846-424
ZINC
ZINC000004097416
http://zinc15.docking.org/substances/ZINC000004097416
PubMed

PubMed

TitleDatePubMed
Auditory brainstem response in premenopausal women taking oral contraceptives.
2003-01
Editor's reply.
2002-12
Implanon.
2002-12
Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism.
2002-12
Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive.
2002-12
Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants.
2002-11
Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone.
2002-11
Persistent vaginal bleeding in a patient with a broken Implanon.
2002-10
An assessment of the use of Implanon in three community services.
2002-10
Bleeding problems and progestogen-only contraception.
2002-10
Contraception failure and wrongful birth claims.
2002-10
Implanon. The new alternative.
2002-10
Ultrasonographic features of the endometrium and the ovaries in women on etonogestrel implant.
2002-10
Sonographic imaging in progestin users and future directions.
2002-10
Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen.
2002-10
Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.
2002-09
Effect of supersaturation and crystallization phenomena on the release properties of a controlled release device based on EVA copolymer.
2002-08-21
Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception.
2002-08
Effects of oral contraceptives with low-dose estrogen and desogestrel on leptin concentrations.
2002-07
Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation.
2002-07
Influence of low-dose oral contraception on peripheral blood lymphocyte subsets at particular phases of the hormonal cycle.
2002-07
Progestin contraceptives.
2002-06-20
Effects of a monophasic pill containing 20 microg ethinylestradiol and 150 microg desogestrel on lipid metabolism in Thai women.
2002-06
[Ultrasonographic and lipid changes in polycystic ovary syndrome according to the type of treatment ].
2002-06
New developments in contraception.
2002-06
[Low-dose combination oral contraceptives use in women with uterine leiomyomas].
2002-06
Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
2002-06
Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
2002-06
Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men.
2002-06
Effect of desogestrel on blood-lipid in relation to its biological activities.
2002-05-25
Long-acting progestogen contraceptives.
2002-05
Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
2002-05
Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke.
2002-05
FDA approves NuvaRing contraceptive implant.
2002-04-27
Oral contraceptives and venous thromboembolism: which are the safest preparations available?
2002-04
Contraceptives and cerebral thrombosis: a five-year national case-control study.
2002-03
Oral contraceptives and venous thromboembolism: a five-year national case-control study.
2002-03
Female hormones and thrombosis.
2002-02-01
Serum concentrations of markers of type I collagen metabolism in women taking monophasic oral contraceptives.
2002-02
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
2002-02
In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring.
2002-01-31
[Third generation oral contraceptives and risk of venous thrombosis].
2002-01-14
[Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
2002-01-10
Prothrombotic effects and clinical implications of third-generation oral contraceptives use.
2002-01
Implantable contraceptives for women.
2002-01
Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII.
2002-01
Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis.
2002-01
Third-generation progestogen type influences hemostatic changes caused by oral contraceptives in Brazilian women.
2001-12
Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation.
2001-11
Implanon: when is the ideal time to insert?
2001-07
Patents

Patents

07667056
1
JP2000511921A
30
JP2002543159A
33
JP2006516602A
3
JP2011528275A
456

Sample Use Guides

In Vivo Use Guide
Take 1 tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) at the same time every day, and at intervals not exceeding 24 hours.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:08:22 GMT 2025
Edited
by admin
on Mon Mar 31 18:08:22 GMT 2025
Record UNII
81K9V7M3A3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYCLESSA COMPONENT DESOGESTREL
Preferred Name English
DESOGESTREL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
VIORELE COMPONENT DESOGESTREL
Brand Name English
DESOGESTREL [EP MONOGRAPH]
Common Name English
desogestrel [INN]
Common Name English
CERAZETTE
Brand Name English
DESOGESTREL [USP-RS]
Common Name English
ORTHO-CEPT COMPONENT DESOGESTREL
Common Name English
ISIBLOOM COMPONENT DESOGESTREL
Brand Name English
VELIVET COMPONENT DESOGESTREL
Common Name English
DESOGESTREL [USAN]
Common Name English
DESOGESTREL [USP MONOGRAPH]
Common Name English
18,19-DINORPREGN-4-EN-20-YN-17-OL, 13-ETHYL-11-METHYLENE-, (17.ALPHA.)-
Common Name English
DESOGESTREL [MART.]
Common Name English
DESOGESTREL [JAN]
Common Name English
BEKYREE COMPONENT DESOGESTREL
Brand Name English
DESOGESTREL [ORANGE BOOK]
Common Name English
ORG 2969
Code English
ENSKYCE COMPONENT DESOGESTREL
Brand Name English
VOLNEA COMPONENT DESOGESTREL
Brand Name English
PIMTREA COMPONENT DESOGESTREL
Brand Name English
KARIVA COMPONENT DESOGESTREL
Common Name English
DESOGEN COMPONENT DESOGESTREL
Common Name English
13-ETHYL-11-METHYLENE-18,19-DINOR-17A-PREGN-4-EN-20-YN-17-OL
Common Name English
MIRCETTE
Brand Name English
DESOGESTREL [HSDB]
Common Name English
DESOGESTREL [VANDF]
Common Name English
ORG-2969
Code English
MIRCETTE COMPONENT DESOGESTREL
Common Name English
DESOGESTREL [MI]
Common Name English
Desogestrel [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC G03AA09
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
NDF-RT N0000011301
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
NDF-RT N0000175602
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-VATC QG03FB10
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-VATC QG03AC09
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
LIVERTOX 285
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-VATC QG03AB05
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-ATC G03FB10
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-ATC G03AC09
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-ATC G03AB05
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
NCI_THESAURUS C776
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
WHO-VATC QG03AA09
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
Code System Code Type Description
MERCK INDEX
m4198
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1173235
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
LACTMED
Desogestrel
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
HSDB
3593
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
IUPHAR
7065
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
INN
4384
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
CAS
54024-22-5
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
WIKIPEDIA
DESOGESTREL
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
DRUG CENTRAL
818
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
DAILYMED
81K9V7M3A3
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL1533
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
NCI_THESAURUS
C47476
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
MESH
D017135
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
DRUG BANK
DB00304
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
ECHA (EC/EINECS)
258-929-4
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
FDA UNII
81K9V7M3A3
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID6022898
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
CHEBI
4453
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
RXCUI
22656
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY RxNorm
SMS_ID
100000083191
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
EVMPD
SUB07003MIG
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
USAN
CC-14
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
PUBCHEM
40973
Created by admin on Mon Mar 31 18:08:22 GMT 2025 , Edited by admin on Mon Mar 31 18:08:22 GMT 2025
PRIMARY
Related Record Type Details
Structure of DESOGESTREL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of ETONOGESTREL
METABOLITE ACTIVE -> PRODRUG
Structure of 3.ALPHA.-HYDROXYDESOGESTREL
METABOLITE INACTIVE -> PARENT
Structure of 3.BETA.-HYDROXYDESOGESTREL
METABOLITE INACTIVE -> PARENT
Structure of ETONOGESTREL
METABOLITE ACTIVE -> PARENT
Structure of 3.ALPHA.-HYDROXY-5.ALPHA.-4,5-DIHYRODESOGESTREL
METABOLITE INACTIVE -> PARENT
Related Record Type Details
Structure of 13-ETHYL-11-METHYLIDENEGON-4-EN-17-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 11-METHYLENELYNESTRENOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 13-ETHYL-11-METHYLIDENEGON-4-EN-17-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ETONOGESTREL
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DESOGESTREL .DELTA. 3-ISOMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESOGESTREL .DELTA. 3-ISOMER
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.8
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of DESOGESTREL
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966